Storia in 4 fonti

Regenxbio to resubmit gene therapy as FDA backtracks on another drug rejection

The agency took another step toward clearing a backlog of Makary-era rejections that appeared to contradict earlier agreements with drugmakers.

Raccontata da

Confronto fonti

4 prospettive sulla stessa storia

AI · summaries

biopharmadive.comStai leggendo1 g fa

Regenxbio to resubmit gene therapy as FDA backtracks on another drug rejection

The agency took another step toward clearing a backlog of Makary-era rejections that appeared to contradict earlier agreements with drugmakers.

originale

endpoints.news22 h fa

Regenxbio to resubmit Hunter syndrome gene therapy as FDA rare disease about-face continues

Regenxbio plans to resubmit its Hunter syndrome gene therapy RGX-121 after the FDA reversed course, saying existing data are sufficient for accelerated approval review.

Leggi questa versione → originale

statnews.com23 h fa

FDA reverses course on Regenxbio’s childhood gene therapy after rejection

The FDA will reconsider approving Regenxbio's experimental gene therapy for a deadly and rare childhood brain disorder it rejected just four months ago.

Leggi questa versione → originale

benzinga.com20 h fa

Regenxbio Gains Fresh Chance As FDA Reconsiders Gene Therapy - Regenxbio (NASDAQ:RGNX)

FDA reverses its rejection of Regenxbio Navsunli, allowing the company to refile its gene therapy application.

Leggi questa versione → originale

Regenxbio to resubmit gene therapy as FDA backtracks on another drug rejection

Confronto fonti

Regenxbio to resubmit gene therapy as FDA backtracks on another drug rejection

Regenxbio to resubmit Hunter syndrome gene therapy as FDA rare disease about-face continues

FDA reverses course on Regenxbio’s childhood gene therapy after rejection

Regenxbio Gains Fresh Chance As FDA Reconsiders Gene Therapy - Regenxbio (NASDAQ:RGNX)

Timeline cronologica

Regenxbio to resubmit gene therapy as FDA backtracks on another drug rejection

FDA reverses course on Regenxbio’s childhood gene therapy after rejection

Regenxbio to resubmit Hunter syndrome gene therapy as FDA rare disease about-face continues

Regenxbio Gains Fresh Chance As FDA Reconsiders Gene Therapy - Regenxbio (NASDAQ:RGNX)

Regenxbio to resubmit gene therapy as FDA backtracks on another drug rejection

Confronto fonti

Regenxbio to resubmit gene therapy as FDA backtracks on another drug rejection

Regenxbio to resubmit Hunter syndrome gene therapy as FDA rare disease about-face continues

FDA reverses course on Regenxbio’s childhood gene therapy after rejection

Regenxbio Gains Fresh Chance As FDA Reconsiders Gene Therapy - Regenxbio (NASDAQ:RGNX)

Timeline cronologica

Regenxbio to resubmit gene therapy as FDA backtracks on another drug rejection

FDA reverses course on Regenxbio’s childhood gene therapy after rejection

Regenxbio to resubmit Hunter syndrome gene therapy as FDA rare disease about-face continues

Regenxbio Gains Fresh Chance As FDA Reconsiders Gene Therapy - Regenxbio (NASDAQ:RGNX)